Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
P/S ratio for Adverum Biotechnologies, Inc. (ADVM)
P/S ratio as of 2023: 21.09
According to Adverum Biotechnologies, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 21.09. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Adverum Biotechnologies, Inc. from 2012 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 21.09 |
| 2022 | 0.00 |
| 2021 | 23.01 |
| 2020 | 0.00 |
| 2019 | 2953.82 |
| 2018 | 1199.33 |
| 2017 | 826.47 |
| 2016 | 722.43 |
| 2015 | 1045.97 |
| 2014 | 21481.08 |
| 2013 | 12114.48 |
| 2012 | 193831.71 |